Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

156.90 -0.79 (-0.50%)
Official Closing Price Updated: 7:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Here Are All the Dividend Kings Beating the S&P 500 in 2025 -- and the 2 That Are the Best Stocks to Buy Now
Via The Motley Fool
Topics Government Stocks World Trade
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash?
Via The Motley Fool
Topics Earnings Economy Government
Johnson & Johnson - Elliott Wave Technical Analysis
We are tracking a potential major bottom forming in Primary wave 2. A clear five-wave move into wave {i} suggests the early stages of an upside trend resumption. 
Via Talk Markets
40-Year-Old Making $4K a Month in Dividends Reveals His Top 8 Stocks — 'We Don't Wear Fancy Clothes or Spend Money on Impressing Others'
Via Benzinga
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?
Medical stocks are usually considered defensive. But have they been too hammered by regulatory changes to hold up this year? 
Via Investor's Business Daily
Topics Animal Testing Economy Government
Nvidia, Johnson & Johnson, Hyundai, Toyota, SoftBank CEOs To Join Trump At White House As He Touts Investment Surge In First 100 Days: Report
Trump to highlight investments from top companies, including Nvidia, J&J, and Toyota, in 'Investing in America' event to mark first 100 days in office. 
Via Benzinga
Topics Government
Plaintiff Sues Eli Lilly, Johnson & Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications
A lawsuit claims Eli Lilly, Johnson & Johnson, and Kaiser Permanente failed to warn consumers about breast cancer risks linked to their antipsychotic drugs Risperdal and Zyprexa. 
Via Benzinga
Topics Lawsuit
AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst
Analysts raise AbbVie price targets after strong Q1 results, driven by Skyrizi, Rinvoq growth and strategic moves in Parkinson's disease treatments. 
Via Benzinga
CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug
The companies are working on treatments for a form of bladder cancer. 
Via Investor's Business Daily
3 Industry Behemoths Are Rewarding Investors With Dividend Bumps
See these three stocks that are among the most important in their industries, which have announced sizable increases in their dividends. 
Via MarketBeat
Topics World Trade
3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.
See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion. 
Via MarketBeat
Topics Artificial Intelligence Economy Government
These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?
Via The Motley Fool
Topics Economy Government Lawsuit
3 Dividend Kings That Have Raised Their Payouts in 2025
Via The Motley Fool
Topics Economy
In the Wake of the Trump Tariff Crash: 2 Unparalleled Dividend Stocks to Buy at a Discount Right Now
Short-term tariff uncertainty marks the perfect opportunity for long-term investors to snag some amazing deals. 
Via The Motley Fool
Topics Economy Government Stocks
Merck (MRK) Reports Q1: Everything You Need To Know Ahead Of Earnings
Global pharmaceutical company Merck (NYSE:MRK) will be reporting results tomorrow before market hours. Here’s what to expect. 
Via StockStory
Bristol-Myers Squibb (BMY) Reports Earnings Tomorrow: What To Expect
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results tomorrow morning. Here’s what investors should know. 
Via StockStory
Trump Administration Considers Lowering US Drug Prices To International Levels: Report
The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations. 
Via Benzinga
Topics Government
JNJ Q1 Earnings: Pipeline Progress and MedTech Execution Drive Guidance Above Expectations
Multinational healthcare company Johnson & Johnson (NYSE:JNJ) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 2.4% year on year to $21.89 billion. The company’s full-year revenue... 
Via StockStory
Topics Earnings World Trade
Why Johnson & Johnson, Chevron, And Flowers Foods Are Winners For Passive Income
Via Benzinga
Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs
Roche to invest $50 billion in U.S. over five years, adding 12,000+ jobs and expanding manufacturing, R&D, and export capacity across eight states. 
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Johnson & Johnson (JNJ): Buy, Sell, or Hold Post Q1 Earnings?
Johnson & Johnson has been treading water for the past six months, recording a small loss of 3.8% while holding steady at $157.30. However, the stock is beating the S&P 500’s 11% decline during that... 
Via StockStory
Topics Stocks
2 Recession-Proof Stocks to Buy With a Better Credit Rating Than the U.S. Government
Via The Motley Fool
Topics Artificial Intelligence Economy Government
From $50 A Month To $1M Portfolio — Investor Shares Top 10 Holdings, Says 'Finally Reached $1M!' Thanks To Relentless Discipline
Via Benzinga
Stocks That Weathered Past Recessions: Expert Shares Picks That Withstood Every Downturn
Stock market expert Jon Erlichman recently shared a review of stock returns during the last six U.S. recessions, highlighting those that have performed well in difficult times. 
Via Benzinga
The SWAN (Sleep Well At Night) Blueprint Revealed
I’ve adopted “SWAN,” which stands for 
Via Talk Markets
Topics Stocks / Equities
3 Top Dividend Stocks Yielding Over 3% to Buy With $500 Right Now
Via The Motley Fool
Topics Bonds
ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot
Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength. 
Via Benzinga
Topics ETFs
Where Will Eli Lilly Be in 5 Years?
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.